Tilray is a global leader in medical cannabis research, cultivation, processing and distribution. We aspire to lead, legitimize and define the future of our industry by building the world’s most trusted cannabis company.

Tilray News

1 day ago

Inner Spirit Holdings Announces Closing of $9.3 Million Convertible Debenture Financing

CALGARY , May 24, 2019 /CNW/ - Inner Spirit Holdings Ltd. ("Inner Spirit" or the "Company") (ISH.CN) today announced it has closed its previously announced offering (the "Offering") of secured convertible...

1 day ago

Veggie Meat and Marijuana: The Hype (Cycle) Is Real

Cannabis and plant-based meat substitutes have real long-term potential, but keep a cool head.

1 day ago

Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks?

Looking for stocks to buy? Get analysis of large-cap stocks like Amazon, Alibaba and Dow Jones stocks GE and Microsoft to see if it's time to buy — or sell.

24 May

11 Pot Stocks Now Listed on the NYSE or Nasdaq

Nearly a dozen marijuana stocks are now listed side by side with time-tested businesses on reputable U.S. exchanges.

24 May

4 Billion-Dollar Marijuana Stocks With Rising Profit Estimates

Despite weaker-than-expected cannabis sales in Canada, some big pot stocks have increasing EPS projections.

23 May

Is Tilray Stock A Buy Right Now? Here's What Earnings, Charts Show

Tilray was 2018's best-performing stock amid a stampede into marijuana stocks, and it got a bump early in May after its quarterly sales beat estimates.

23 May

Tilray Boosts Export Capability With EU Manufacturing License, GMP Certification

Tilray, Inc. (NASDAQ: TLRY) announced Thursday that its wholly owned subsidiary Tilray Portugal Unipessoal Lda. received a standard manufacturing license for its Cantanhede, Portugal-based Biocant Park...

23 May

Tilray's Portugal sub receives GMP certification for export of dried cannabis

Tilray Inc. said its Portugal-based wholly-owned subsidiary, Tilray Portugal Unipessoal Lda. has received a Good Manufacturing Practices (GMP) certification and a standard manufacturing license, which...

23 May

Tilray® Boosts International Export Capacity with Manufacturing License and GMP Certification at EU Campus

Tilray, Inc. (“Tilray” or “the Company”) (TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal...

23 May

Tetra Bio-Pharma: Diamond In The Rough

Editor's note: Seeking Alpha is proud to welcome James Mase as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also...

Load more

About Tilray

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

A proud pioneer, we are the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers on five continents.

Tilray's experience is unmatched worldwide. Our team professionals on the ground in 7 countries serves thousands of patients around the globe. Our flagship cultivation facility is among the most advanced in the world.

Tilray is the first GMP-certified medical cannabis producer to supply cannabis flower and extracts. All of our products are produced with meticulous care to ensure the highest quality, consistency and purity for our patients.

We are committed to scientific research that leads to an improved quality of life for patients in a time frame that matters. We partner with leading hospitals and universities to advance the clinical applications of cannabinoids.

Tilray takes tremendous pride in our customer service, patient outreach, and physician interaction. We recognize the importance of tracking potential adverse events as well as therapeutic benefits in order to ensure the safety of our patients.



Governor Howard Dean
Michael Steele
The Honourable Lloyd...
Joschka Fischer
Jaime Gama
The Honourable Alexa...
Rt Hon Sir Donald Mc...
María Lorena Gutiérr...
James O’Brien
Dr. Lorna Marsden
Brendan Kennedy
Chief Executive Officer
Mark Castaneda
Chief Financial Officer
Woody Pastorius
Chief Revenue Officer
Adine Fabiani-Carter
Chief Marketing Officer
Catherine Jacobson
Regulatory & Medical Affairs
Christy Zhou
General Counsel, Tilray Canada
Josh Eades
VP, Chief Science Officer
Scott Krompocker
VP, Operations, Tilray Nanaimo
Philippe Lucas
VP, Patient Research and Access
John Andonoff
VP, Sales & Marketing
Marla Luther
Director of Business Development, Europe
Steven Yoo
Director of Corporate Investments
Sean Carney
Director of Business Development & Government Rela...
Françoise Lévesque
Master Horticulturist
Tom McGaugh
Director of Finance

Participation in events

  • CannMed
  • 300 E Green St, Pasadena, CA 91101, USA


Nanaimo British Columbia, Canada
22 Mar 2019
London Ontario, Canada
13 Feb 2019
$ 43.88
Share volume:
160.951 K
Total value:
12.625 M
Market cap:
3.535 B